trending Market Intelligence /marketintelligence/en/news-insights/trending/yOAtQIPtGlwoQWDOo94Dpw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

GSK licenses 3 Ebola vaccines to Sabin Vaccine Institute

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


GSK licenses 3 Ebola vaccines to Sabin Vaccine Institute

The Sabin Vaccine Institute has licensed technology from GlaxoSmithKline PLC to develop vaccines for the Ebola and Marburg viruses, which the U.K. pharmaceutical giant acquired through the purchase of specialist vaccines-maker Okairos AG in 2013.

SNL Image

Under the agreement, nonprofit Sabin will gain certain licensing and patent rights to three vaccine candidates for the Ebola Zaire and Ebola Sudan viruses, plus the closely related Marburg virus. No vaccines have so far been developed to prevent infection with these three viruses, which cause hemorrhagic fever and death in as many as 50% of cases, according to a joint press release issued Aug. 6.

An ongoing outbreak of the Ebola Zaire virus in the Democratic Republic of Congo has killed 1,600 people and has been declared a public health emergency of international concern by the World Health Organization.

Okairos originally developed the three vaccine candidates in collaboration with the U.S. National Institutes of Health. After buying Okairos, GSK further advanced the vaccines using its proprietary ChAd3 platform. The Ebola Zaire vaccine was advanced to phase 2 development while the Ebola Sudan vaccine was tested in three phase 1 trials and is about to be tested in another phase 1 trial. The Marburg vaccine is undergoing a phase 1 study in the U.S.

The vaccines have so far been administered to 5,000 adults and 600 children during the trials and have demonstrated a strong safety profile and immune response.

Washington, D.C.-based Sabin has entered into a research collaboration with the Vaccine Research Center at the U.S. National Institute of Allergy and Infectious Diseases to further develop the vaccines and eventually move them toward regulatory approval.

Financial terms of the deal were not disclosed.